OUST heads into its June 17 earnings print with a split personality — a stock up 53% over the past month that just shed 16% in a single week, with its own founder selling millions into the strength.
The insider story is the loudest signal right now. Founder and CTO Mark Frichtl sold more than 300,000 shares across multiple tranches on May 26, collecting roughly $12 million at prices between $39 and $45. COO Darien Spencer added another 30,000 shares sold at $45, and a C-level executive also trimmed. The 90-day net is still positive at around 730,000 shares and $27 million in value — which tells you much of that net is likely option-related — but the concentrated May 26 activity reads less like routine plan execution and more like insiders taking advantage of the run. The stock has since retreated to $38.52, below several of those sale prices, which is worth noting as context heading into the print.
Short positioning has been quietly unwinding throughout this period, which complicates the bearish read. Short interest fell about 12% on the week to roughly 8.9% of the free float — still meaningful, but down from closer to 10% when the stock was climbing through late May. The borrow market has loosened considerably. Cost to borrow has collapsed nearly 45% on the week to just 0.28%, a fraction of where it traded through most of May. Availability is running at around 302% — three shares available for every one currently borrowed — well above the 52-week tightest level of 146% recorded in early May. Shorts are not fighting the tape here; they appear to be stepping back as the stock pulls in. The ORTEX short score has drifted lower all week, from 59.6 on May 28 to 52.7 now, reflecting the same de-escalation.
Options positioning has grown modestly more defensive, though not dramatically so. The put/call ratio is running at 0.44, about 1.2 standard deviations above its 20-day average of 0.37. That's elevated by recent norms but far from extreme — the 52-week high is 1.11, and the current level sits comfortably in the bottom half of the annual range. What the options market seems to be saying is that traders are buying some insurance ahead of June 17 without making a strong directional bet. The defensive tilt is real but restrained.
The Street is broadly positive, though the most recent moves carry some nuance. Rosenblatt raised its target to $53 from $40 on May 27, maintaining its Buy — a vote of confidence after the price run. A fresh Buy initiation from Amerx came in at $43. But Cantor Fitzgerald downgraded to Neutral from Overweight on May 7, right after the prior earnings print triggered a 14% single-day drop, and notably did not attach a new price target. The consensus mean target of $46.85 sits above the current price, giving around 22% implied upside on paper. The bull case centres on $169.4M in FY25 revenue, consistent estimate beats, and the Rev8 sensor cycle. The bear case points to negative operating margins and a valuation that, at roughly 10x forward sales, leaves little room for execution slips. EPS surprise ranks in the 95th percentile of the universe — one of the strongest beats records around — but quality factors remain weak, with negative ROA and a low Piotroski score.
The last two earnings events offer a contrasting template. The May 2026 print produced a 14% drop on the day followed by an 18% recovery over the subsequent five sessions — a painful short-term reaction that reversed sharply. The prior event was more modest: a 4% gain on the day, then a 4% drift lower over the week. Peers had a rough week alongside OUST: AEVA fell 20%, PRZO dropped 26%, and UMAC shed 28%, suggesting sector-wide pressure rather than anything specific to Ouster. The June 17 print therefore becomes the next pivot — whether the stock's 53% one-month run holds a floor or the pattern of sharp post-earnings reversals reasserts itself.
See the live data behind this article on ORTEX.
Open OUST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
